Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516331 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Electronic (PDF)Add to Basket
Hard CopyAdd to Basket
EnterprisewideAdd to Basket
Live Chat Live Help Software for Website

Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions

Datamonitor, April 2011, Pages: 70


  Description  
    
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), the BRIC markets (Brazil, Russia, India, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011–15.

Features and benefits
- An overview generic uptake and market sizing
- Insight into the key drivers and resistors to generic uptake in key the developed and emerging markets.
- An examination of the major generics players and the strategies they have implemented in both the developed and emerging markets.
- Insight into future opportunities for generics players

Highlights
- In response to rising healthcare expenditure, governments in developed markets are looking bolster generic uptake in order to contain costs. Physician prescribing by international non-proprietary name (INN), in addition to automatic substitution and pharmacist incentives, are key tools to drive generic uptake.
- In the US, despite the addition of many new customers and the continued drive to increase generic uptake as a result of the healthcare reform law, generics companies are set to experience further downward pricing pressures and will be forced to operate with ever-decreasing margins, focusing on consolidation and cost-cutting.
- The BRIC countries represent a key growth market for the generics industry. Uptake of generics in these markets will be driven by continued population expansion, increased prosperity, and expanding healthcare coverage.

Your key questions answered
- Evaluate the drivers and resistors to generic uptake in the US, EU, Japan and BRIC markets
- Gain insight into the deal types between companies to bolster their position in generics markets
- Identify which key small molecules are facing patent expiry and provide opportunities for generic producers



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds